Literature DB >> 11768614

Expression of angiogenic factors and tumor progression in human neuroblastoma.

H Komuro1, S Kaneko, M Kaneko, Y Nakanishi.   

Abstract

PURPOSE: The growth and metastasis of malignant tumors is largely dependent on angiogenesis. Angiogenic factors produced by tumor cells are known to promote tumor angiogenesis. The aim of this study was to investigate which angiogenic factor is the most important in the progression of neuroblastoma (NB). PROCEDURE: The relative expression levels of vascular endothelial growth factor-A (VEGF-A), VEGF-C, basic fibroblast growth factor (bFGF), and platelet-derived endothelial growth factor (PD-ECGF/TP) were studied in 28 NB tumor specimens by real-time quantitative reverse transcriptase/polymerase chain reaction (RT-PCR). The relationships between the expression of these four angiogenic factors and stage, patient age, primary site, MYCN copy number, and lymph node metastasis were analyzed.
RESULTS: High VEGF-A expression was correlated with stage 4 disease (blood-borne metastasis). No relationship between VEGF-A expression and age, primary site, MYCN copy number, or lymph node metastasis was found. The expression of VEGF-C, bFGF, or PD-ECGF/TP showed no correlation with stage, age, primary site, MYCN copy number, or lymph node metastasis.
CONCLUSIONS: Our findings suggest that VEGF-A, but not VEGF-C, bFGF, or PD-ECGF/TP, may be associated with progression of NB. VEGF-A could be a target for antiangiogenic therapy for disseminated NB.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11768614     DOI: 10.1007/s004320100293

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  18 in total

1.  Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2.

Authors:  Jürgen Becker; Helena Pavlakovic; Fabian Ludewig; Fabiola Wilting; Herbert A Weich; Romulo Albuquerque; Jayakrishna Ambati; Jörg Wilting
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

2.  PROX1 lymphatic density correlates with adverse clinicopathological factors, lymph node metastases and survival in neuroblastomas.

Authors:  Pramila Ramani; Aimie Norton; Michelle S Somerville; Margaret T May
Journal:  J Neurooncol       Date:  2012-03-01       Impact factor: 4.130

3.  Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma.

Authors:  Yvan H Chanthery; W Clay Gustafson; Melissa Itsara; Anders Persson; Christopher S Hackett; Matt Grimmer; Elise Charron; Slava Yakovenko; Grace Kim; Katherine K Matthay; William A Weiss
Journal:  Sci Transl Med       Date:  2012-01-04       Impact factor: 17.956

4.  LYVE-1 upregulation and lymphatic invasion correlate with adverse prognostic factors and lymph node metastasis in neuroblastoma.

Authors:  Pramila Ramani; Josiah V Dungwa; Margaret T May
Journal:  Virchows Arch       Date:  2012-01-13       Impact factor: 4.064

5.  Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III.

Authors:  Kathrin Niemöller; Christian Jakob; Ulrike Heider; Ivana Zavrski; Jan Eucker; Olaf Kaufmann; Kurt Possinger; Orhan Sezer
Journal:  J Cancer Res Clin Oncol       Date:  2003-04-17       Impact factor: 4.553

Review 6.  Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors.

Authors:  Julia Glade Bender; Darrell J Yamashiro; Elizabeth Fox
Journal:  Oncologist       Date:  2011-10-31

7.  Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.

Authors:  Shakeel Modak; Brian H Kushner; Ellen Basu; Stephen S Roberts; Nai-Kong V Cheung
Journal:  Pediatr Blood Cancer       Date:  2017-01-23       Impact factor: 3.167

8.  Inhibition of the focal adhesion kinase and vascular endothelial growth factor receptor-3 interaction leads to decreased survival in human neuroblastoma cell lines.

Authors:  Elizabeth A Beierle; Xiaojie Ma; Jerry E Stewart; Michael Megison; William G Cance; Elena V Kurenova
Journal:  Mol Carcinog       Date:  2012-10-12       Impact factor: 4.784

9.  Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion.

Authors:  Ivana Zavrski; Cord Naujokat; Kathrin Niemöller; Christian Jakob; Ulrike Heider; Corinna Langelotz; Claudia Fleissner; Jan Eucker; Kurt Possinger; Orhan Sezer
Journal:  J Cancer Res Clin Oncol       Date:  2003-07-08       Impact factor: 4.553

10.  Identification of novel biomarkers in neuroblastoma associated with the risk for bone marrow metastasis: a pilot study.

Authors:  J Osman; S Galli; M Hanafy; X Tang; A Ahmed
Journal:  Clin Transl Oncol       Date:  2013-04-04       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.